Table 2.
Clinical and biochemical comparison of acromegalic patients grouped according to disease control (n=137)
| Control group (Group A) (n=64) |
Acromegalic patients with active disease (Group B) (n=41) |
Acromegalic patients with controlled disease (Group C) (n=32) |
p |
|||
| p1 | p2 | p3 | ||||
| Age (years) Mean±SD | 47.9±13.5 | 49.3±12 | 46.5±13.1 | NS | NS | NS |
| Female (n)/male (n) | 41/23 | 25/16 | 21/11 | NS | NS | NS |
| BMI (kg/m2) Mean±SD | 28.9±5.1 | 30.5±6.9 | 29.5±5.2 | NS | NS | NS |
| Creatinine (mg/dL) Mean±SD | 0.73±0.2 | 0.67±0.14 | 0.73±0.19 | NS | NS | NS |
| eGFR Mean±SD | 100.5±17.9 | 105.7±15.3 | 102.6±18.8 | NS | NS | NS |
| ALT Mean±SD | 27.0±17.6 | 16.5±6.0 | 16.9±8.0 | 0.001 | 0.001 | NS |
| ALP (U/L) Mean±SD | 83.6±34 | 88.4±31.3 | 71.7±25.1 | NS | NS | 0.03 |
| Calcium (mg/dL) Mean±SD | 9.1±0.48 | 9.5±0.55 | 9.0±0.39 | 0.001 | NS | 0.001 |
| Phosphorus (mg/dL) Mean±SD | 3.5±0.45 | 3.9±0.55 | 3.6±0.41 | 0.001 | NS | 0.03 |
| Magnesium (mg/dL) Mean±SD | 2±0.14 | 1.8±0.21 | 1.9±0.15 | <0.001 | 0.02 | NS |
| PTH (pg/mL) Mean±SD | 50.4±27.3 | 53.9±21.3 | 55.1±30.3 | NS | NS | NS |
| 25(OH)D (ng/mL) Mean±SD | 23.5±12 | 19.2±10 | 25.7±13.4 | NS | NS | NS |
| CTX Mean±SD | 0.34±0.17 | 0.62±0.35 | 0.44±0.22 | <0.001 | NS | 0.017 |
| GH (ng/ml) Mean±SD | 2.1±0.64 | 16.8±7.4 | 1.1±0.7 | <0.001 | NS | <0.001 |
| IGF-1 ULN Mean±SD | 0.55±0.16 | 1.75±0.82 | 0.75±0.28 | <0.001 | 0.01 | <0.001 |
P1: Difference between Groups A and B; P2: Difference between Groups A and C; P3: Difference between Groups B and C; P<0.05 statistically significant, significant p values are shown in bold; SD: Standard deviation; BMI: Body mass index; ALP: Alkaline phosphatase; ALT: Alanine aminotransferase; PTH: Parathyroid hormone; CTX: Cross-linked C-telopeptide of type I collage; GH: Growth hormone; IGF-1 ULN: Insulin-like growth factor-1 upper limit of normal.